At 7.0% CAGR, the Europe Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is Projected to be Worth US$ 460.7 million by 2030, Says Business Market Insights

According to Business Market Insights research, the Europe fluorescence in-situ hybridization (FISH) imaging systems market was valued at US$ 268.0 million in 2022 and is expected to reach US$ 460.7 million by 2030, registering a CAGR of 7.0% from 2022 to 2030. Rising prevalence of target disorders and increasing R&D investments in in-vitro diagnostics attributed to the Europe fluorescence in-situ hybridization (FISH) imaging systems market expansion.        

The Europe fluorescence in-situ hybridization (FISH) imaging systems market is driven by continued investments in research and development (R&D) activities related to in-vitro diagnostics (IVD). With its unique capability to visualize specific DNA sequences within cellular environments, the FISH technique has emerged as a key procedure in the modern diagnostics ecosystem, particularly in detecting genetic disorders and rare diseases. An upsurge in R&D funding in IVD has catalyzed transformative advancements in FISH imaging systems by allowing researchers to create cutting-edge platforms providing enhanced image quality with features supporting streamlined automation, culminating in more accurate and rapid diagnostic processes. PNA FISH, a novel diagnostic method that uses FISH with peptide nucleic acid (PNA) probes, combines the ease of traditional staining procedures with the exceptional performance of PNA probes to provide rapid and accurate diagnoses of contagious diseases, which makes PNA FISH suitable for routine application and enables clinical microbiology laboratories to report important information for patient therapy within a time frame that is not possible using classic biochemical methods.

On the contrary, high cost of fish imaging systems and procedures hampers the Europe fluorescence in-situ hybridization (FISH) imaging systems market.  

Based on product, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into instruments, consumables, accessories, and software. The consumables held 51.6% share of Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 138.3 million. It is projected to garner US$ 241.3 million by 2030 to expand at 7.2% CAGR during 2022–2030. 

In terms of application, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnostic, and others. The cancer diagnosis segment held 48.6% share of Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 130.5 million. It is projected to garner US$ 230.3 million by 2030 to expand at 7.4% CAGR during 2022–2030.

Based on end users, the Europe fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organizations, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held 77.0% share of Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022, amassing US$ 206.3 million. It is projected to garner US$ 356.6 million by 2030 to expand at 7.1% CAGR during 2022–2030.

By country, the Europe fluorescence in-situ hybridization (FISH) imaging systems market has been categorized into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 30.4% share of Europe fluorescence in-situ hybridization (FISH) imaging systems market in 2022. It was assessed at US$ 81.35 million in 2022 and is likely to hit US$ 149.12 million by 2030, exhibiting a CAGR of 7.9% during 2022–2030.      

Key players operating the Europe fluorescence in-situ hybridization (FISH) imaging systems market Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, and Applied Spectral Imaging, among others.

• Bio-View Ltd, Apr-2023 Partnership   ANGLE Plc, a global leader in liquid biopsy, entered a collaboration with BioView Ltd to develop a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer using ANGLE's FDA-cleared Parsortix PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess HER2 expression and/or gene amplification in CTCs.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com